- ISIN
- US7835548279
- CUSIP
- 783554827
- Issuer
- Rydex Funds
- Inception Date
- Mar 31, 1998
- Category
- Health & Biotech Equities
- Min. Investment
- $2,500
- Distribution Policy
- Distributing
- Asset Class
- Equity
- Asset Class Size
- Mid-Cap
- Asset Class Style
- Blend
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
RYOIX Performance Chart
Rydex Biotechnology Fund (RYOIX) is up 9.2% since the beginning of the year. RYOIX is currently trading at $82 per share. Investors who bought $1,000 worth of RYOIX shares 5 years ago would now be looking at an investment worth $1,284.
Loading charts...
Returns By Period
Rydex Biotechnology Fund (RYOIX) has returned 9.21% so far this year and 45.71% over the past 12 months. Over the last ten years, RYOIX has returned 9.92% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.
Rydex Biotechnology Fund
- 1D
- 0.06%
- 1M
- 3.18%
- YTD
- 9.21%
- 6M
- 6.91%
- 1Y
- 45.71%
- 3Y*
- 14.07%
- 5Y*
- 5.13%
- 10Y*
- 9.92%
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
RYOIX Monthly Returns History
Based on dividend-adjusted daily data since Jan 4, 1999, RYOIX's average daily return is +0.06%, while the average monthly return is +1.12%. At this rate, an investment would double in approximately 5.2 years.
Historically, 57% of months were positive and 43% were negative. The best month was Feb 2000 with a return of +45.3%, while the worst month was Mar 2000 at -26.7%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 4 months.
On a daily basis, RYOIX closed higher 51% of trading days. The best single day was Oct 13, 2008 with a return of +11.7%, while the worst single day was Mar 14, 2000 at -13.1%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 2.11% | 2.24% | -2.25% | 0.97% | 4.72% | 1.21% | 9.21% | ||||||
| 2025 | 5.41% | -0.25% | -6.18% | 0.33% | -3.60% | 3.27% | 4.09% | 4.90% | 5.45% | 8.84% | 8.10% | -2.14% | 30.62% |
| 2024 | -1.30% | 2.19% | -0.07% | -7.29% | 5.25% | 4.63% | 6.05% | 1.74% | -2.77% | -1.44% | 1.12% | -7.94% | -0.95% |
| 2023 | 2.26% | -4.48% | 0.13% | 1.79% | -2.56% | 0.93% | 0.94% | -0.46% | -4.30% | -6.10% | 6.19% | 12.98% | 6.06% |
| 2022 | -10.49% | -3.08% | 3.88% | -9.95% | -0.33% | 0.00% | 5.24% | -3.63% | -3.52% | 7.83% | 6.41% | -4.26% | -13.04% |
| 2021 | 5.28% | -2.16% | -4.42% | 4.33% | -3.40% | 9.21% | -1.55% | 3.76% | -5.22% | 0.25% | -4.43% | 1.52% | 2.05% |
Benchmark Metrics
Rydex Biotechnology Fund has an annualized alpha of 6.04%, beta of 1.01, and R2 of 0.44 versus S&P 500 Index. Calculated based on daily prices since January 04, 1999.
- This fund captured 110.24% of S&P 500 Index gains but only 92.95% of its losses - a favorable profile for investors.
- R2 of 0.44 means the benchmark explains less than half of this fund's behavior - treat beta with caution or consider switching to a more representative benchmark.
- Alpha
- 6.04%
- Beta
- 1.01
- R²
- 0.44
- Upside Capture
- 110.24%
- Downside Capture
- 92.95%
Expense Ratio
RYOIX has a high expense ratio of 1.36%, indicating above-average management fees.
Return for Risk
Risk / Return Rank
RYOIX ranks 79 for risk / return — better than 79% of mutual funds on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Rydex Biotechnology Fund (RYOIX) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| RYOIX | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +0.28 | ||
| Sortino ratioReturn per unit of downside risk | +0.54 | ||
| Omega ratioGain probability vs. loss probability | 1.38 | 1.37 | +0.01 |
| Calmar ratioReturn relative to maximum drawdown | 5.39 | 2.78 | +2.61 |
| Martin ratioReturn relative to average drawdown | 19.62 | 12.44 | +7.18 |
Dividends
Dividend History
Rydex Biotechnology Fund provided a 11.51% dividend yield over the last twelve months, with an annual payout of $9.41 per share.
| Period | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | $9.41 | $9.41 | $9.42 | $0.00 | $0.90 | $15.77 | $6.95 | $7.20 | $9.89 | $4.70 | $0.00 | $1.28 |
Dividend yield | 11.51% | 12.57% | 14.61% | 0.00% | 1.29% | 19.39% | 7.28% | 8.58% | 14.11% | 5.38% | 0.00% | 1.45% |
Monthly Dividends
The table displays the monthly dividend distributions for Rydex Biotechnology Fund. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||||||
| 2025 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $9.41 | $9.41 |
| 2024 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $9.42 | $9.42 |
| 2023 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2022 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.90 | $0.90 |
| 2021 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $15.77 | $15.77 |
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Rydex Biotechnology Fund. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Rydex Biotechnology Fund was 74.43%, occurring on Jul 10, 2002. Recovery took 2567 trading sessions.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
Dot-com crash2000–2002 | -74.43%Jul 2002 | 2y 4mo | 10y 2mo | 12y 6moMar 2000 - Sep 2012 |
2016 bear market2016 | -40.76%Feb 2016 | 6mo 26d | 3y 10mo | 4y 4moJul 2015 - Dec 2019 |
Bear market2022 | -33.66%Jun 2022 | 9mo 13d | 3y 4mo | 4y 1moSep 2021 - Oct 2025 |
COVID crash2020 | -25.73%Mar 2020 | 2mo 21d | 1mo 22d | 4mo 13dDec 2019 - May 2020 |
2014 bear market2014 | -23.25%Apr 2014 | 1mo 17d | 6mo 12d | 7mo 29dFeb 2014 - Oct 2014 |
Drawdown Indicators
| RYOIX | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -74.43% | -56.78% | -17.65% |
Max Drawdown (1Y)Largest decline over 1 year | -8.43% | -9.10% | +0.67% |
Max Drawdown (3Y)Largest decline over 3 years | -23.47% | -18.90% | -4.57% |
Max Drawdown (5Y)Largest decline over 5 years | -33.66% | -25.43% | -8.23% |
Max Drawdown (10Y)Largest decline over 10 years | -33.66% | -33.92% | +0.26% |
Current DrawdownCurrent decline from peak | 0.00% | -1.80% | +1.80% |
Average DrawdownAverage peak-to-trough decline | -27.59% | -10.71% | -16.88% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 2.31% | 2.03% | +0.28% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Build a portfolio with RYOIX
Add Rydex Biotechnology Fund to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with RYOIX